{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260327464200/en/Tozorakimab-met-primary-endpoint-in-both-OBERON-and-TITANIA-Phase-III-trials-in-patients-with-COPD", "message": "News view counter 628713 successfully enlarged"}